intoxicant.wiki2catechol4school
Compound

SU-11739

Also called N-Methyl-N-2-propynylindanamine

Original Wikipedia articleen.wikipedia.org/wiki/SU-11739 revision used (24 October 2026)

Why a "revision used" link? Anyone can edit Wikipedia at any time, so the article you open today may not say what it said when we read it. This link opens the exact version we read on 24 October 2026, frozen as it was. It is the only way to check that every quote on this page matches its source word for word. Newer versions may correct or change things. When we re-check this page against a newer version, the edit log records it. How we cite

Overview

SU-11739 (other developmental code names AGN-1133, J-508; also known as N-methyl-N-propargyl-1-aminoindane) is an experimental monoamine oxidase inhibitor (MAOI) that was never marketed.[1–5] WP

It is a dual or non-selective irreversible monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B) inhibitor, with preference for inhibition of MAO-B over MAO-A. It is less selective for MAO-B inhibition than AGN-1135 (racemic rasagiline) or rasagiline. In addition to its MAOI activity, SU-11739 has been reported to have strong activity as a catecholamine releasing agent. Similarly to rasagiline, but unlike selegiline and desmethylselegiline, SU-11739 is not a monoaminergic activity enhancer (MAE).[3–7] WP

The drug is the racemic N-methylated analogue of rasagiline. It is also a ring-cyclized analogue of pargyline with about 20 times the MAOI potency of pargyline.[2][3][4][8] WP

SU-11739 was discovered before rasagiline and was patented in 1965. WP

Chemistry

Formula
C13H15N PC
CAS number
1875-49-6 PC
Molar mass (g/mol)
185.26 PC
IUPAC name (computed by PubChem)
N-methyl-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine PC
SMILES
CN(CC#C)C1CCC2=CC=CC=C12 PC
InChIKey
CSVGVHNFFZWQJU-UHFFFAOYSA-N PC
PubChem CID
15179
IUPAC name
N-methyl-N-prop-2-ynyl-2,3-dihydro-1H-inden-1-amine WP

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

Awaiting sourceChecked against PsychonautWiki and TripSit as each pull runs. This box is replaced as soon as a source has data.

User reports

Erowid erowid.org

Listings
Awaiting sourceExperience Vault listing and report categories.
Top stories
Awaiting sourceShort summaries of the most-read reports, each linked, saying only what the report says.

Bluelight bluelight.org

Listings
Awaiting sourceTrip report threads and this substance's discussion forum.
Top stories
Awaiting sourceShort summaries of the most-read reports, each linked, saying only what the report says.

Reddit reddit.com

Listings
Awaiting sourceTrip report posts and the relevant subreddits.
Top stories
Awaiting sourceShort summaries of the most-read reports, each linked, saying only what the report says.

Pop culture

No references added yet.

Add a reference

Registered users can add songs, films, books, shows, games and art about this substance. Link a source that names the substance, such as the work's Wikipedia article, a review or an interview, not only the work itself. Entries are voted on and moderated like every other value on this page.

Opens when accounts launch.

Sources

  1. Journal / agency Tipton KF, Fowler CJ, McCrodden JM, Strolin Benedetti M. The enzyme-activated irreversible inhibition of type-B monoamine oxidase by 3-(4-[(3-chlorophenyl)methoxy]phenyl)-5-[(methylamino) methyl]-2-oxazolidinone methanesulphonate (compound MD 780236) and the enzyme-catalysed oxidation of this compound as competing reactions. Biochem J. January 1983. doi:10.1042/bj2090235 · PMID 6847610 · PMC1154077
  2. Journal / agency Finberg JP. The discovery and development of rasagiline as a new anti-Parkinson medication. Journal of Neural Transmission. February 2020. doi:10.1007/s00702-020-02142-w · PMID 31974721
  3. Journal / agency Weinreb O, Amit T, Bar-Am O, Youdim MB. Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Progress in Neurobiology. November 2010. doi:10.1016/j.pneurobio.2010.06.008 · PMID 20600573
  4. Journal / agency Youdim MB, Bakhle YS. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. British Journal of Pharmacology. January 2006. doi:10.1038/sj.bjp.0706464 · PMID 16402116 · PMC1760741
  5. Journal / agency Miklya I. Essential difference between the pharmacological spectrum of (-)-deprenyl and rasagiline. Pharmacol Rep. June 2014. doi:10.1016/j.pharep.2013.11.003 · PMID 24905523
  6. Journal / agency Miklya I. (-)-deprenil, az N-metilprogargilamin-1-aminoindan (J-508) és a J-508 dezmetil analógjának (rasagilin) összehasonlító farmakológiai analízise. Neuropsychopharmacol Hung. March 2008. PMID 18771016
  7. Journal / agency Yen TT, Dalló J, Knoll J. The aphrodisiac effect of low doses of (-) deprenyl in male rats. Pol J Pharmacol Pharm. 1982. PMID 6821215
  8. Journal / agency Huebner CF, Donoghue EM, Plummer AJ, Furness PA. N-methyl-n-2-propynyl-l-indanamine. A protent monoamine oxidase inhibitor. Journal of Medicinal Chemistry. November 1966. doi:10.1021/jm00324a009 · PMID 5972038

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.